Claims
- 1. A method of treating a mammal suffering from conditions associated with a pathologically excessive amount of protein glycosylation comprising administering to the mammal an effective amount of a tetracycline sufficient to inhibit said pathologically excessive amount of protein glycosylation.
- 2. The method of claim 1, wherein a protein which is subject to said pathologically excessive amount of protein glycosylation is a somatic protein with exposed amino groups.
- 3. The method of claim 2, wherein said somatic protein with exposed amino groups is selected from the group consisting of collagen, laminin, albumin, lens crystallins and fibrin.
- 4. The method of claim 2, where in said protein is associated with pathological conditions including diabetes mellitus, scleroderma and progeria.
- 5. The method of claim 3, wherein said protein is collagen and said pathologically excessive amount of collagen glycosylation results in a pathologically excessive amount of collagen crosslinking.
- 6. The method of claim 5, wherein said pathologically excessive amount of collagen crosslinking is associated with conditions including diabetes mellitus, scleroderma and progeria.
- 7. The method according to claim 1, wherein the tetracycline is a dedimethylaminotetracycline.
- 8. The method according to claim 7, wherein the dedimethylaminotetracycline is selected from the group consisting of 4-dedimethylaminotetracycline, 4-dedimethylamino-5-oxytetracycline, 4-dedimethylamino-7chlorotetracycline, 4-hydroxy-4-dedimethylaminotetracycline, 5a,6-anhydro-4-hydroxy-4-dedimethylaminotetracycline, 6.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12a-deoxytetracycline, 12a-deoxy-4-deoxy-4-dedimethylaminotetracycline, 12a, 4a-anhydro-4-dedimethylaminotetracycline, 7-dimethylamino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline and 4-dedimethylamino-11-hydroxy-12a-deoxytetracycline.
- 9. The method according to claim 1, wherein the tetracycline is selected from the group consisting of 6a-benzylthiomethylenetetracycline, tetracyclinonitrile, the mono-N-alkylated amide of tetracycline, 6-fluoro-6-demethyltetracycline, 11a-chlorotetracycline, tetracycline pyrazole, 6.alpha.-deoxy-5-hydroxy-4-dedimethylaminodoxycycline and 12a-deoxytetracycline and its derivatives.
- 10. The method according to claim 1, wherein the tetracycline is administered in an amount of from about 0.1 mg/kg per day to about 50.0 mg/kg per day.
- 11. The method according to claim 10, wherein the tetracycline is administered in an amount of from about 0.3 mg/kg per day to about 15.0 mg/kg per day.
BACKGROUND OF THE INVENTION
The present application is a continuation-in-part of U.S. patent application Ser. No. 07/977,549 filed on Nov. 17, 1992, now abandoned.
Government Interests
This invention was made with Government support under R37 DE-03987, awarded by The National Institute of Dental Research. The Government has certain rights in the invention.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4935412 |
McNamara et al. |
Jun 1990 |
|
5045538 |
Schneider et al. |
Sep 1991 |
|
5258371 |
Golub et al. |
Nov 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
977549 |
Nov 1992 |
|